Company Description
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2005 |
| IPO Date | Mar 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 298 |
| CEO | Michael Metzger |
Contact Details
Address: 730 Third Avenue, 9th Floor New York, New York 10017 United States | |
| Phone | 781 419 1400 |
| Website | syndax.com |
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| Employer ID | 32-0162505 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer and Director |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer and Principal Accounting Officer |
| Luke J. Albrecht J.D. | General Counsel and Corporate Secretary |
| Steven Closter | Chief Commercial Officer |
| Dr. Nicholas A.J. Botwood B.Sc., MBBS | Head of Research and Development and Chief Medical Officer |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Sharon Klahre | Vice President of Investor Relations and Communications |
| Averi Price | Senior Vice President of Legal and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 2, 2026 | 10-Q | Quarterly Report |
| Nov 2, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 144 | Filing |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 4, 2026 | 10-Q | Quarterly Report |
| Aug 4, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 8-K | Current Report |
| Jul 8, 2026 | 144 | Filing |
| Jun 12, 2026 | 144 | Filing |
| Jun 11, 2026 | 144 | Filing |